Pfizer Stock Forecast for 2022 - 2025 - 2030

Updated on 12/02/2022

Stock Rating
3
Price Target
$52.30
Consensus
Outperform
Upside
2.39%
Analysts
16
Stock Rating
3
Upside
2.39%
Analysts
16
Price Target
$52.30

Pfizer Stock Forecast and Price Target

The average target price for Pfizer's stock set by sixteen renowned analysts in recent months is $52.30, representing a potential upside of approximately 2.39% from its last closing price if met by 2023. This estimation is based on a high estimate of $75.00 and a low estimate of $44.00. If you are looking to invest in the stock, it's important to research and compare different companies.

$52.30

2.39% Upside

Outperform
Outperform

Pfizer Fair Value Forecast for 2022 - 2025 - 2030

In the last three years, Pfizer's Price has grown by 47.33%, from $41.58 to $61.26. For the next year, analysts are expecting Fair Value to reach $98.96 – an increase of 61.54%. By 2030, professionals predict that Pfizer's Fair Value will decrease by 26.70%, to $44.91.

2022 Fair Value Forecast
$98.96
2023 Fair Value Forecast
$75.68
2024 Fair Value Forecast
$62.51
2025 Fair Value Forecast
$60.15
2026 Fair Value Forecast
$58.49
2027 Fair Value Forecast
$58.91
2028 Fair Value Forecast
$48.37
2029 Fair Value Forecast
$44.91
2030 Fair Value Forecast
$44.91
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
ABBV Stock Forecast AbbVie Outperform 7
$161.63 $164.23 -1.94%
COST Stock Forecast Costco Wholesale Outperform 13
$503.86 $557.59 12.13%
AZN Stock Forecast AstraZeneca PLC Outperform 18
£112.00 £136.08 28.85%
ABT Stock Forecast Abbott Laboratories Outperform 14
$107.93 $128.88 5.62%
BMY Stock Forecast Bristol-Myers Squibb Outperform 2
$80.88 $79.05 2.50%

Pfizer Revenue Forecast for 2022 - 2025 - 2030

In the last three years, Pfizer's Revenue has grown by 99.11%, from $40.83B to $81.29B. For the next year, analysts are expecting Revenue to reach $105.90B – an increase of 30.28%. By 2030, professionals predict that Pfizer's Revenue will decrease by 34.71%, to $53.07B.

2022 Rev Forecast
$105.90B
2023 Rev Forecast
$79.92B
2024 Rev Forecast
$69.26B
2025 Rev Forecast
$67.30B
2026 Rev Forecast
$65.06B
2027 Rev Forecast
$64.48B
2028 Rev Forecast
$55.63B
2029 Rev Forecast
$53.31B
2030 Rev Forecast
$53.07B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
AMGN Stock Forecast Amgen Hold 7
$285.94 $246.51 -9.77%
CSL Stock Forecast CSL Outperform 16
$298.66 $228.01 -28.44%
BDX Stock Forecast Becton, Dickinson and Outperform 17
$250.83 $272.08 8.04%

Pfizer Dividend per Share Forecast for 2022 - 2025 - 2030

In the last three years, Pfizer's Dividend per Share has grown from $1.36 to $1.56 – a 14.71% increase. Next year, analysts are expecting Dividend per Share to reach $1.62 – an increase of 3.85%. Over the next nine years, the forecast is for Dividend per Share to grow by 8.33%.

2022 DPS Forecast
$1.62
2023 DPS Forecast
$1.68
2024 DPS Forecast
$1.72
2025 DPS Forecast
$1.77
2026 DPS Forecast
$1.72
2027 DPS Forecast
$1.67
2028 DPS Forecast
$1.67
2029 DPS Forecast
$1.67
2030 DPS Forecast
$1.69
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
MMM Stock Forecast 3M Hold 16
$125.99 $147.79 1.20%
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥4.60k ¥0.00 13.12%
CL Stock Forecast Colgate-Palmolive Outperform 18
$77.75 $80.37 4.18%

Pfizer Free Cash Flow Forecast for 2022 - 2025 - 2030

In the last three years, Pfizer's Free Cash Flow has grown by 115.77%, rising from $13.84B to $29.87B. For next year, analysts predict Free Cash Flow of $34.79B, which would mean an increase of 16.47%. In 2030, professionals predict that Pfizer's Free Cash Flow will decrease by 49.08%, reaching $15.21B.

2022 FCF Forecast
$34.79B
2023 FCF Forecast
$30.67B
2024 FCF Forecast
$24.18B
2025 FCF Forecast
$23.37B
2026 FCF Forecast
$22.93B
2027 FCF Forecast
$21.67B
2028 FCF Forecast
$16.77B
2029 FCF Forecast
$15.65B
2030 FCF Forecast
$15.21B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BAYN Stock Forecast Bayer Outperform 7
55.03€ 67.79€ 43.56%
A Stock Forecast Agilent Technologies Outperform 17
$156.12 $157.63 3.77%
BAS Stock Forecast BASF Outperform 11
47.86€ 78.27€ 14.92%

Pfizer Net Income Forecast for 2022 - 2025 - 2030

In the last three years, Pfizer's Net Income has grown by 97.07%, rising from $11.15B to $21.98B. For next year, analysts predict Net Income of $40.98B, which would mean an increase of 86.43%. According to professionals, by 2030, Pfizer's Net Income will have decreased by 14.38%, falling down to $18.82B.

2022 NI Forecast
$40.98B
2023 NI Forecast
$31.82B
2024 NI Forecast
$25.70B
2025 NI Forecast
$24.66B
2026 NI Forecast
$23.88B
2027 NI Forecast
$23.83B
2028 NI Forecast
$20.02B
2029 NI Forecast
$18.84B
2030 NI Forecast
$18.82B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
4519 Stock Forecast Chugai Pharmaceutical Hold 18
¥3.66k ¥0.00 23.09%
BIIB Stock Forecast Biogen Outperform 11
$301.85 $242.78 7.67%
BNTX Stock Forecast BioNTech Outperform 12
$169.47 $0.00 20.92%

Pfizer EBITDA Forecast for 2022 - 2025 - 2030

In the last three years, Pfizer's EBITDA has grown, rising from $13.47B to $31.95B – a growth of 137.24%. In the next year, analysts believe that EBITDA will reach $48.44B – an increase of 51.62%. By 2030, professionals believe that Pfizer's EBITDA will have decreased by 39.14%, falling to $19.44B.

2022 EBITDA Forecast
$48.44B
2023 EBITDA Forecast
$37.31B
2024 EBITDA Forecast
$31.16B
2025 EBITDA Forecast
$29.88B
2026 EBITDA Forecast
$29.39B
2027 EBITDA Forecast
$29.07B
2028 EBITDA Forecast
$22.41B
2029 EBITDA Forecast
$19.65B
2030 EBITDA Forecast
$19.44B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
ALC Stock Forecast Alcon Outperform 15
CHF65.48 CHF0.00 29.15%
BN Stock Forecast Danone Outperform 18
50.83€ 62.59€ 10.17%
4503 Stock Forecast Astellas Pharma Outperform 18
¥2.13k ¥0.00 12.83%

Pfizer EBIT Forecast for 2022 - 2025 - 2030

Pfizer's EBIT has grown In the last three years, rising from $7.36B to $26.85B – a growth of 264.99%. In the next year, analysts believe that EBIT will reach $44.31B – an increase of 65.07%. By 2030, professionals believe that Pfizer's EBIT will decrease by 19.82%, reaching $21.52B – a concerning trend for the company.

2022 EBIT Forecast
$44.31B
2023 EBIT Forecast
$33.76B
2024 EBIT Forecast
$27.33B
2025 EBIT Forecast
$27.59B
2026 EBIT Forecast
$26.95B
2027 EBIT Forecast
$27.08B
2028 EBIT Forecast
$22.66B
2029 EBIT Forecast
$21.42B
2030 EBIT Forecast
$21.52B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
ALNY Stock Forecast Alnylam Pharmaceuticals Outperform 7
$220.25 $236.31 8.06%
BAX Stock Forecast Baxter International Outperform 17
$52.38 $65.40 22.18%
4523 Stock Forecast Eisai Hold 18
¥9.78k ¥0.00 -32.48%

Pfizer EPS Price Prediction Forecast for 2022 - 2025 - 2030

In the last three years, Pfizer's EPS has grown by 47.33%, from $3.00 to $4.42. For the next year, analysts are expecting EPS to reach $7.14 – an increase of 61.54%. By 2030, professionals predict that Pfizer's EPS will decrease by 26.70%, to $3.24.

2022 EPS Forecast
$7.14
2023 EPS Forecast
$5.46
2024 EPS Forecast
$4.51
2025 EPS Forecast
$4.34
2026 EPS Forecast
$4.22
2027 EPS Forecast
$4.25
2028 EPS Forecast
$3.49
2029 EPS Forecast
$3.24
2030 EPS Forecast
$3.24
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
CHD Stock Forecast Church & Dwight Hold 11
$82.24 $81.90 -0.29%
ERF Stock Forecast Eurofins Scientific Hold 18
68.36€ 0.00€ 53.60%
BIM Stock Forecast bioMérieux Outperform 18
97.48€ 113.60€ 6.18%